Prescribing cascade in an older adult with bipolar disorder

Year 2025, Volume: 5 Issue: 2, 54 - 57, 29.04.2025

Songül Gültekin , Mustafa Çetin , Mehmet İlkin Naharci

https://doi.org/10.56016/dahudermj.1548871

Abstract

The prescribing cascade begins when medication side effects are misinterpreted as new symptoms, leading to the addition of new drugs.
This case involves a 75-year-old female with a history of Parkinson’s disease, dementia, bipolar disorder, and diabetes. She presented with complaints of bradykinesia, difficulty walking, and inability to move independently. The patient had been on long-term antipsychotic treatment (olanzapine) for bipolar disorder, leading to parkinsonian symptoms, which were mistakenly diagnosed as dementia. Consequently, the patient was prescribed donepezil, an antidementia medication. During this period, she developed depression and urinary incontinence, for which duloxetine and fesoterodine fumarate were added to her treatment. The patient’s functionality and quality of life further deteriorated due to inappropriate medication use and polypharmacy.
After evaluation, a decision was made to gradually discontinue several of the patient’s medications, including memantine, fesoterodine fumarate, and donepezil, while reducing the olanzapine dose. Following these adjustments, her mobility improved, appetite increased, and overall condition stabilized.
This case highlights the need to closely monitor older adults with mental health problems taking multiple medications for adverse drug reactions. The frequency of monitoring should be individualized according to the patient’s risk factors and treatment response. It also contributes to increased awareness among healthcare professionals and caregivers of the prescribing cascade among these individuals.

Keywords

Prescribing cascade , Older patient , Antipsychotic medications

References

• Wyles H, Rehman HU. Inappropriate polypharmacy in the elderly. Eur J Intern Med. 2005 Sep;16(5):311-3. doi: 10.1016/j.ejim.2005.02.006. PMID: 16137542.
• Mortazavi SS, Shati M, Keshtkar A, et al. Defining polypharmacy in the elderly: a systematic review protocol. BMJ Open 2016;6:e010989. doi:10.1136/bmjopen-2015-010989
• Halter, Jeffrey B., et al., editors. Hazzard’s Geriatric Medicine and Gerontology. 6th ed., McGraw-Hill, 2009.
• Katz, S., Down, T.D., Cash, H.R., & Grotz, R.C. (1970) Progress in the development of the index of ADL. The Gerontologist, 10(1), 20-30.
• Lawton MP, Brody EM Gerontologist. 1969;9(3):179-186.
• Journal of Psychiatric Research, 12(3): 189-198, 1975.
• GDS.Retrieved July 2, 2012, from http://www.stanford.edu/~yesavage/GDS.html.
• Aggarwal P, Woolford SJ, Patel HP. Multi-Morbidity and Polypharmacy in Older People: Challenges and Opportunities for Clinical Practice. Geriatrics (Basel). 2020;5(4):85. Published 2020 Oct 28. doi:10.3390/geriatrics5040085
• Hammond T, Wilson A. Polypharmacy and falls in the elderly: a literature review. Nurs Midwifery Stud. 2013 June;2(2):171-5. doi: 10.5812/nms.10709. Epub 2013 Jun 27. PMID: 25414854; PMCID: PMC4228551.
• Ayani N, Morimoto T, Sakuma M, Kikuchi T, Watanabe K, Narumoto J. Antipsychotic Polypharmacy Is Associated With Adverse Drug Events in Psychiatric Inpatients: The Japan Adverse Drug Events Study. J Clin Psychopharmacol. 2021;41(4):397-402. doi:10.1097/JCP.0000000000001416
• Husa, A. P., Moilanen, J., Murray, G. K., et al. (2014). Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. The British Journal of Psychiatry, 205(1), 45–50.
• Vita, A., De Peri, L., & Sacchetti, E. (2015). Antipsychotics, brain volume, and neurocognition: A systematic review and meta-analysis of magnetic resonance imaging findings. Psychological Medicine, 45(3), 515–528.
• Singh R, Sadiq NM. Cholinesterase Inhibitors. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544336